ABSTRACT
The genetic determinants of fractional exhalation of nitric oxide (FeNO), a marker of lung inflammation, are understudied in Black populations. Alpha globin, which is polymorphic in Black populations, restricts nitric oxide signaling in arterial endothelial cells. We hypothesized that an alpha globin gene deletion would be associated with higher FeNO in a cross-sectional study of 643 healthy Black adults. We found that 30% were heterozygous and 4.7% were homozygous for the deletion. A prespecified additive genetic model found no association with FeNO; however, a post hoc recessive genetic model suggested that FeNO may be higher among homozygotes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The original study was supported by project ES011185 from the National Institute of Environmental Health Sciences; and MO1-RR-30 from the National Center for Research Resources, Clinical Research Centers Program, National Institutes of Health. The current analysis was supported in part by the Divisions of Intramural Research, National Institute of Allergy and Infectious Diseases project AI001150 (A.P.R., J.M.J, C.M.C, J.G.N., M.P. F., H.C.A), National Heart, Lung, and Blood Institute (NHLBI) project HL006196 (A.P.R., H.C.A.). This work was also funded in part by NHLBI grants NIH R01-HL107590 and R01HL153641 (L.G.Q.) and the Durham VA Medical Center Research Service (J.B.W.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID or NHLBI. The content of this publication does not necessarily reflect the view or policy of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the government. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided oral and written informed consent with approval from the Duke University Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We have an incorporated the results of a post-hoc analysis to the manuscript.
Data Availability
Deidentified data and statistical code from this article will be available to researchers. Data can be obtained upon reasonable request by contacting the corresponding author.
